Default company panoramic image

Nemucore Medical Innovations, Inc.

Developing life saving Precision Medicines for the treatment of Acute Myeloid Leukemia & Ovarian Cancer. Leveraging >$37M in non-dilutive product funding.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Wellesley, MA, US
  • Currency USD
  • Founded February 2008
  • Employees 6
  • Incorporation Type C-corp
  • Website

Company Summary

Nemucore Medical Innovations, Inc. is dedicated to the development and commercialization of Precision Medicines for the treatment of highly lethal cancers, particularly Acute Myeloid Leukemia (AML), Myelodysplastic syndromes (MDS) as well as ovarian, breast, and lung cancer.

Our lead product NMI-900 and its companion diagnostic are ready to enter clinical trials for AML and MDS at Memorial Sloan-Kettering and Moffitt Cancer Centers.


  • 422de7a5 5338 427f 8f2c 698e37e408b9
    Chairman, CEO and President

    An entrepreneur and NCI funded oncology researcher, Tim is the inventor and developer of several precision medicines and has dedicated his life to the commercialization of technology to cure cancer. Tim worked in PwC's personalize medicine advisory practice as a manager and was twice honored with the PwC Chairman's Award. Tim earned a PhD in molecular biophysics from the Medical College of Virginia at VCU and MBA from the Boston University.

  • 74cf4bb6 cf35 45b6 a241 2a12156e2238
    Director of Operations

    Mrs. Stephenson coordinates the financial and infrastructure aspects of operations. Previously Nicole worked in PwC's Health Industries Advisory practice, specializing clinical trial operational efficiencies and regulatory compliance issues. Nicole worked as a researcher at several top biotech companies in Cambridge MA, MGH, and FSU. She holds a Master of Science in Biological Science from FSU and a MBA from BU.

Previous Investors